Looking for Stenotrophomonas maltophilia treatment: in vitro activity of ceftazidime/avibactam alone and in combination with aztreonam

• DOI: 10.1080/1120009x.2023.2247199
• Publication Date: 2023-08-24T07:55:48Z
• Authors: Enrica Maddalena ...; Sofia Denicolò; Stefania Stolfa; Lidia Dalfino; Davide Fiore Bavaro; Annalisa Saracino; Luigi Ronga; Raffaele Del Prete; Adriana Mosca
• Keywords: Ceftazidime/avibactam; Stenotrophomonas maltophilia; Aztreonam; Avibactam; Trimethoprim

AbstractDuring the Sars-Cov-2 pandemic, Stenotrophomonas maltophilia (S.maltophilia) secondary pulmonary infections have increased, especially in critically ill patients, highlighting need for new therapeutic options. Trimethoprim-sulfamethoxazole (SXT) is treatment of choice but increase resistant strains or adverse drug reactions limited its clinical use. Recently ceftazidime/avibactam (CZA) has been approved multi (MDR) Gram-negative bacteria infections, including hospital acquired pneumonia. The aim this study was to evaluate vitro activity alone and combination with aztreonam (ATM) against S. isolates by E-test method. Susceptibility SXT levofloxacin (LEV) also investigated. Our results showed 22% resistance CZA, 2% 26% LEV. CZA ATM demonstrated synergistic 86% strains, all those CZA. provides a option severe respiratory patients.Keywords: maltophiliaaztreonamceftazidime/avibactamsynergyantimicrobial susceptibilitynosocomial Disclosure statementNo potential conflict interest reported author(s).